Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 7Recruiting 3Completed 2Withdrawn 1

Sponsor Class

OTHER 44INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × gallium 68 PSMA-11 × Clear all
NCT05114746 2026-05-08

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Novartis

Phase 2 Completed
94 enrolled
Genitourinary

Prostatic Neoplasms

NCT03822871 2024-03-21

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Cancer Targeted Technology

Phase 1 Completed
17 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡